Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.

Key Points

• This analysis aims to compare the annual pharmacy costs of tirzepatide and semaglutide for achieving treatment endpoints in patients with type 2 diabetes.
• Analyzed pharmacy cost data for tirzepatide and semaglutide patients in the UK
• Evaluated annual costs per patient achieving treatment targets
• Compared costs across different treatment endpoints
• Tirzepatide showed lower annual pharmacy costs compared to semaglutide
• Cost differences were more significant at stricter treatment targets
• Majority of endpoints favored tirzepatide in terms of cost efficiency